ArticleWorld journal of gastrointestinal oncology2025
Analysis of serum S100A12, soluble advanced glycation end products receptor, and gut microbiome in elderly patients with colorectal cancer.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microbiota in the Tumor Metastatic Cascade: Emerging Evidence Across Invasion, Circulation, and Colonization.International journal of molecular sciences · 2026Review
- Stage-Specific carcinogenic mechanisms and intervention strategies for pksArchives of microbiology · 2026Review
- Associations between serum biomarkers and gut microbial imbalance in predicting chemotherapy response in colorectal cancer: A retrospective analysis.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) ranks among the most prevalent malignancies in elderly populations, and chemotherapy resistance remains a critical clinical challenge. Emerging evidence highlights the interplay between chronic inflammation, gut microbiome dysbiosis, and CRC progression. Proinflammatory cytokines [
aimTo analyze the correlation between serum levels of S100A12, sRAGE, gut microbiome dysbiosis, and systemic inflammation in elderly patients with CRC and to assess their predictive value for chemotherapy efficacy.
methodsA retrospective analysis was conducted on the clinical data of 120 elderly patients with advanced-stage CRC who visited our hospital from August 2023 to May 2024. These patients were enrolled in the study group. Additionally, 120 healthy individuals undergoing routine health check-ups during the same period were selected as the control group. Serum S100A12, sRAGE, IL-6, and TNF-α levels were measured by ELISA, and fresh stool samples were collected before chemotherapy to analyze gut microbiome composition in the study group. Follow-up observations were conducted after chemotherapy. Pearson correlation analysis was used to explore the relationship between serum S100A12, sRAGE levels, and gut microbiome dysbiosis in patients with CRC. The predictive diagnostic value of pre-chemotherapy serum S100A12 and sRAGE levels for chemotherapy efficacy was assessed using receiver operating characteristic curves.
resultsPre-chemotherapy serum S100A12, sRAGE, IL-6, and TNF-α levels were significantly elevated in patients with CRC
conclusionElevated serum S100A12 and sRAGE in elderly patients with CRC reflected gut microbiome dysbiosis and systemic inflammation, driven by IL-6/TNF-α signaling. Their post-chemotherapy decline parallels microbiota restoration, supporting a microbiome-inflammation-biomarker axis. The combined biomarker model offers robust clinical utility for chemotherapy efficacy prediction and personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.